Evolocumab

CHEMBL2364655 Phase 4 Одобрено Antibody
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This injectable antibody blocks PCSK9, a protein that destroys the liver's LDL receptors, allowing more bad cholesterol to be cleared from the bloodstream. It dramatically lowers LDL cholesterol and reduces the risk of heart attack and stroke.

Терапевтические области

Механизм действия

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This injectable antibody blocks PCSK9, a protein that destroys the liver's LDL receptors, allowing more bad cholesterol to be cleared from the bloodstream. It dramatically lowers LDL cholesterol and reduces the risk of heart attack and stroke.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Evolocumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2364655. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.